Financial Ratios Marker Therapeutics, Inc.
Equities
MRKR
US57055L2060
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.430 USD | -0.69% |
|
-3.38% | -4.03% |
| 11-14 | Marker Therapeutics Q3 net loss narrows to $2 mln | RE |
| 11-13 | Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -39.26 | -43.38 | -36.5 | -35.36 | -35.5 | |||||
Return on Total Capital | -42.9 | -51.7 | -45.06 | -54.16 | -42.62 | |||||
Return On Equity % | -80.37 | -117.42 | -94.14 | -83.47 | -65.81 | |||||
Return on Common Equity | -80.37 | -117.42 | -94.14 | -83.47 | -65.81 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -3.94K | -2.14K | -190 | -214.6 | -104.33 | |||||
SG&A Margin | 2.24K | 1.04K | 142.23 | 225.78 | 64.35 | |||||
EBITDA Margin % | -6.08K | -3.01K | -301.29 | -356.14 | - | |||||
EBITA Margin % | -6.19K | -3.18K | -332.23 | -440.37 | -168.69 | |||||
EBIT Margin % | -6.19K | -3.18K | -332.23 | -440.37 | -168.69 | |||||
Income From Continuing Operations Margin % | -6.15K | -3.37K | -332.06 | -424.2 | -162.82 | |||||
Net Income Margin % | -6.15K | -3.37K | -332.06 | -248.76 | -162.82 | |||||
Net Avail. For Common Margin % | -6.15K | -3.37K | -332.06 | -424.2 | -162.82 | |||||
Normalized Net Income Margin | -3.84K | -1.99K | -205.92 | -265.06 | -101.29 | |||||
Levered Free Cash Flow Margin | -4.16K | -1.05K | -232.09 | -306.27 | -108.14 | |||||
Unlevered Free Cash Flow Margin | -4.16K | -1.05K | -232.09 | -306.27 | -108.14 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.01 | 0.02 | 0.18 | 0.13 | 0.34 | |||||
Fixed Assets Turnover | 0.04 | 0.06 | 0.45 | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.81 | 3.56 | 2.14 | 5.57 | 6.36 | |||||
Quick Ratio | 3.49 | 3.28 | 1.82 | 5.25 | 6.22 | |||||
Operating Cash Flow to Current Liabilities | -2.95 | -2.11 | -3.47 | -5.35 | -3.15 | |||||
Average Days Payable Outstanding | 38.07 | 53.05 | 47.17 | 36.13 | 27.54 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 44.82 | 26.98 | 38.86 | - | - | |||||
Total Debt / Total Capital | 30.95 | 21.25 | 27.98 | - | - | |||||
LT Debt/Equity | 43.4 | 25.57 | 35.91 | - | - | |||||
Long-Term Debt / Total Capital | 29.97 | 20.14 | 25.86 | - | - | |||||
Total Liabilities / Total Assets | 40.05 | 35.44 | 43.06 | 17.95 | 15.73 | |||||
EBIT / Interest Expense | - | - | - | - | - | |||||
Total Debt / EBITDA | -0.45 | -0.34 | -0.3 | - | - | |||||
Net Debt / EBITDA | 0.33 | 0.87 | 0.17 | 1.28 | - | |||||
Total Debt / (EBITDA - Capex) | -0.33 | -0.31 | -0.25 | - | - | |||||
Net Debt / (EBITDA - Capex) | 0.24 | 0.8 | 0.14 | 1.28 | - | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 118.95 | 166.01 | 625.9 | -5.76 | 99.06 | |||||
Gross Profit, 1 Yr. Growth % | 46.71 | 44.2 | -35.5 | -15.96 | -3.22 | |||||
EBITDA, 1 Yr. Growth % | 26.65 | 31.44 | -27.25 | -30.64 | - | |||||
EBITA, 1 Yr. Growth % | 28.22 | 36.67 | -24.15 | -26.32 | -23.75 | |||||
EBIT, 1 Yr. Growth % | 28.22 | 36.67 | -24.15 | -26.32 | -23.75 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 33.97 | 45.89 | -28.53 | -28.97 | -23.6 | |||||
Net Income, 1 Yr. Growth % | 33.97 | 45.89 | -28.53 | -72.48 | 30.28 | |||||
Normalized Net Income, 1 Yr. Growth % | 33.97 | 37.5 | -24.76 | -28.15 | -23.93 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 29.83 | -9.87 | -34.52 | -32.72 | -25.05 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 2.33K | 4.48 | -19.64 | - | - | |||||
Total Assets, 1 Yr. Growth % | -1.61 | 49.37 | -49.48 | -50.24 | 28.58 | |||||
Tangible Book Value, 1 Yr. Growth % | -37.97 | 60.86 | -55.44 | -28.31 | 32.06 | |||||
Common Equity, 1 Yr. Growth % | -37.97 | 60.86 | -55.44 | -28.31 | 32.06 | |||||
Cash From Operations, 1 Yr. Growth % | 3.15 | 36.16 | -1.13 | -39.05 | -33.64 | |||||
Capital Expenditures, 1 Yr. Growth % | 2.68K | -66.16 | 57.93 | - | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 74.1 | -28.88 | 61.13 | -31.34 | -29.71 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 74.1 | -28.88 | 61.13 | -31.34 | -29.71 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 50.53 | 141.34 | 339.43 | 63.3 | 36.96 | |||||
Gross Profit, 2 Yr. CAGR % | -61.43 | 45.45 | -3.56 | -48.27 | -9.81 | |||||
EBITDA, 2 Yr. CAGR % | - | 29.02 | -2.21 | -43.8 | - | |||||
EBITA, 2 Yr. CAGR % | -55.85 | 32.38 | 1.82 | -39.23 | -25.05 | |||||
EBIT, 2 Yr. CAGR % | -55.85 | 32.38 | 1.82 | -39.23 | -25.05 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -55.95 | 39.8 | 2.11 | -42.09 | -26.34 | |||||
Net Income, 2 Yr. CAGR % | -55.95 | 39.8 | 2.11 | -55.65 | -40.12 | |||||
Normalized Net Income, 2 Yr. CAGR % | -55.95 | 35.72 | 1.71 | -40.36 | -26.07 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -71.94 | 8.17 | -23.36 | -46.03 | -28.99 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 1.1K | 403.83 | -8.37 | - | - | |||||
Total Assets, 2 Yr. CAGR % | -14.33 | 21.23 | -13.13 | -49.86 | -20.01 | |||||
Tangible Book Value, 2 Yr. CAGR % | -32.12 | -0.11 | -15.34 | -43.48 | -2.7 | |||||
Common Equity, 2 Yr. CAGR % | -32.12 | -0.11 | -15.34 | -43.48 | -2.7 | |||||
Cash From Operations, 2 Yr. CAGR % | 14.13 | 22.15 | 16.03 | -22.37 | -36.4 | |||||
Capital Expenditures, 2 Yr. CAGR % | 740.34 | 188.96 | -26.89 | - | - | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -49.21 | 7.86 | 7.05 | -11.62 | -30.53 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -49.21 | 7.86 | 7.05 | -11.62 | -30.53 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 36.62 | 81.99 | 248.37 | 92.14 | 74.44 | |||||
Gross Profit, 3 Yr. CAGR % | 53.73 | -40.14 | 10.91 | -27.2 | -36.26 | |||||
EBITDA, 3 Yr. CAGR % | - | - | 6.59 | -25.4 | - | |||||
EBITA, 3 Yr. CAGR % | 36.01 | -35.65 | 9.95 | -20.38 | -34.45 | |||||
EBIT, 3 Yr. CAGR % | 36.01 | -35.65 | 9.95 | -20.38 | -34.45 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 37.75 | -34.34 | 11.78 | -21.2 | -36.48 | |||||
Net Income, 3 Yr. CAGR % | 37.75 | -34.34 | 11.78 | -34.04 | -36.48 | |||||
Normalized Net Income, 3 Yr. CAGR % | 35.75 | -35.62 | 11.49 | -21.21 | -35.32 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -19.31 | -58.6 | -8.64 | -36.07 | -39.79 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 431.35 | 173.24 | - | - | |||||
Total Assets, 3 Yr. CAGR % | 106.5 | 3.12 | -9.45 | -27.86 | -31.37 | |||||
Tangible Book Value, 3 Yr. CAGR % | 95.53 | -9.5 | -23.68 | -19.9 | -25 | |||||
Common Equity, 3 Yr. CAGR % | 95.53 | -9.5 | -23.68 | -19.9 | -25 | |||||
Cash From Operations, 3 Yr. CAGR % | 30.74 | 23.51 | 13.84 | -6.38 | -26.32 | |||||
Capital Expenditures, 3 Yr. CAGR % | - | 176.78 | 136.26 | - | - | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 61.33 | -44.35 | 23.3 | -17.79 | -18.12 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 61.33 | -44.35 | 23.3 | -17.79 | -18.12 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 118 | 74.27 | 98.63 | |||||
Gross Profit, 5 Yr. CAGR % | - | - | 27.57 | -43.53 | -11.34 | |||||
EBITA, 5 Yr. CAGR % | 36.22 | 35.98 | 21.14 | -37.11 | -13.17 | |||||
EBIT, 5 Yr. CAGR % | 36.22 | 35.98 | 21.14 | -37.11 | -13.17 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -3.37 | 76.35 | 22.2 | -37.56 | -12.92 | |||||
Net Income, 5 Yr. CAGR % | -3.37 | 76.35 | 22.2 | -43.88 | -12.92 | |||||
Normalized Net Income, 5 Yr. CAGR % | -3.35 | 76.27 | 20.95 | -37.56 | -13 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -42.01 | -5.13 | -20.96 | -54.01 | -23.96 | |||||
Total Assets, 5 Yr. CAGR % | 47 | 53.78 | 46.05 | -22.72 | -13.83 | |||||
Tangible Book Value, 5 Yr. CAGR % | 5.06 | 48.05 | 39.9 | -25.03 | -15.89 | |||||
Common Equity, 5 Yr. CAGR % | 5.06 | 48.05 | 39.9 | -25.03 | -15.89 | |||||
Cash From Operations, 5 Yr. CAGR % | 34.13 | 33.18 | 26.16 | 2.57 | -9.81 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -4.63 | -15.41 | 35.22 | -33.04 | -8.58 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -4.63 | -15.41 | 35.22 | -33.04 | -8.58 |
- Stock Market
- Equities
- MRKR Stock
- Financials Marker Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















